RC方案治疗复发/难治套细胞淋巴瘤的临床效果

CLINICAL EFFICACY OF CLADRIBINE COMBINED WITH RITUXIMAB IN TREATMENT OF RECURRENT OR REFRACTORY MANTLE CELL LYMPHOMA

目的探讨克拉屈滨联合利妥昔单抗(RC)方案治疗复发/难治套细胞淋巴瘤(MCL)的临床效果及安全性。方法收集并分析2014年8月—2017年1月就诊于我科的13例复发/难治MCL病人的临床资料。13例病人均至少接受3周期RC方案治疗。主要研究终点为总缓解率(ORR)和完全缓解(CR)率,次要研究终点为无进展生存(PFS)时间和2年总生存(OS)率,观察记录治疗相关的不良反应。结果本组病人的ORR为84.6%,CR率为33.3%。截至2018年12月1日,发生治疗相关死亡2例,其中1例病人死于感染性休克,1例病人死于多脏器衰竭。本组病人中位PFS时间为14个月,2年OS率为82%。主要不良反应:发生3~4级血液学毒性反应7例(53.8%),发生继发感染5例(38.5%)。结论RC方案治疗复发/难治MCL效果好,不良反应可耐受。

Objective To investigate the clinical efficacy and safety of the regimen of cladribine combined with rituximab (RC) in the treatment of recurrent/refractory mantle cell lymphoma (MCL). Methods The clinical data of 13 patients with recurrent/refractory MCL who visited our department from August 2014 to January 2017 were collected. All patients received at least three cycles of chemotherapy with the RC regimen. The primary endpoints were overall response rate (ORR) and complete response (CR) rate, and the secondary endpoints were progression-free survival (PFS) time and 2-year overall survival (OS) rate. Treatment-related adverse events were observed and recorded. Results The ORR and CR rate of these patients were 84.6% and 33.3%, respectively. Up to December 1, 2018, there were two cases of treatment-related deaths due to septic shock and multiple organ failure, respectively. The median PFS time was 14 months and the 2-year OS rate was 82%. Major adverse events included grade 3-4 hematological toxicity in 7 patients (53.8%) and secondary infection in 5 patients (38.5%). Conclusion RC regimen has good clinical efficacy in the treatment of recurrent/refractory MCL, and its adverse events are well tolerated among patients.